Abstract
Reboxetine is a novel antidepressant that has been shown to be effective in the treatment of major depressive disorders. The present experiment was designed to assess whether it affects the cognitive and psychomotor skills necessary for optimum function in everyday life. Ten healthy male volunteers received reboxetine 0.5 mg, 1 mg or 4 mg, amitriptyline 25 mg, or matched placebo with and without alcohol (0.6 mg kg−1) in a double-blind 10-way crossover study. A psychometric test battery was administered at baseline and at 1, 2.25, 3.5, 6 and 9 h post-dose. The results showed that reboxetine had little or no effect on performance at any dose, compared with placebo. Amitriptyline, however, with and without alcohol, lowered critical flicker fusion threshold compared with placebo and/or reboxetine at all test points (e.g. at 3.5 h: 28.51 vs 30.33 Hz; P<0.05); increased reaction time (e.g. 619 vs 540 ms; P<0.05); increased tracking error (e.g. 16.34 vs 8.54 RMS units; P<0.05); and slowed short-term memory scanning (e.g. 742 vs 590 ms; P<0.05). It is concluded that reboxetine at doses of 4 mg and below is free from disruptive effects on cognitive function and psychomotor performance, and that it does not act synergistically with alcohol, in contrast to amitriptyline.
Keywords: reboxetine, amitriptyline, alcohol, antidepressants, cognitive function, psychomotor performance
Full Text
The Full Text of this article is available as a PDF (203.5 KB).